# A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

> **NCT01281631** · PHASE2 · COMPLETED · sponsor: **Neuraltus Pharmaceuticals, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** NP001
- **DRUG:** NP001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01281631
- **Lead sponsor:** Neuraltus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2012-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281631, "A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01281631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*